Second dose of CAR t therapy tested for tough lymphoma cases

NCT ID NCT05794958

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times

Summary

This early-phase study is testing whether a second infusion of the CAR T-cell therapy axicabtagene ciloleucel (Axi-Cel-2) is safe for adults with high-risk large B-cell lymphoma whose cancer came back or didn't respond to the first standard CAR T treatment. About 20 participants will be closely monitored for side effects for 28 days after the second infusion. The goal is to find a way to better control this aggressive cancer, though lifelong monitoring may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Stanford University

    RECRUITING

    Palo Alto, California, 94305, United States

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.